Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“The last 2 years have seen the establishment of cyclindependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC in view of the OS benefit seen in several trials,(36-42) both in the first- and second-line settings, substantial PFS benefit and goo…”
BackgroundSelf-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Self-citationOverall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Self-citationBurstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationOverall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791
Self-citationSkipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 904
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Self-citationLyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Spring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
Self-citationCDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023: Featured Updates to the NCCN Guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 453
Self-citationBraal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., Fasching, P. A., Crown, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305488 · Cited by 405
Self-citationBreast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
“For example, the combination of a CDK4/6 inhibitor named ribociclib and AIs, or tamoxifen, has better efficacy than endocrine therapy alone [257].”
BackgroundBreast Cancer Survivorship, Quality of Life, and Late Toxicities
Nardin, S., Mora, E., Varughese, F. M., D'Avanzo, F., Vachanaram, A. R., Rossi, V., Saggia, C., Rubinelli, S., & Gennari, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00864 · Cited by 330
“Today, the median overall survival in patients with HER2-positive metastatic breast cancer is the range of 50 months (9–11); the recent introduction of CDK 4/6 inhibitors in the clinic also significantly improved survival in ER+ patients (12, 13).”
BackgroundBurstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., Litton, J. K., Macrae, E. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01392 · Cited by 317
“The safety profile observed in the OS analysis report was comparable.(12) The most common grade 3 or 4 AEs in the ribociclib and placebo after a median of 2 years of treatment exposure were neutropenia (63.”
MethodPrimary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Lu, Y.-S., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Cardoso, F., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3032 · Cited by 287
“As previously described, a separate medication randomization list was produced by or under the responsibility of Novartis Drug Supply Management using a validated system that automated the random assignment of medication numbers to medication packs containing each of the study treatments (1, 5).”
BackgroundMethodSelf-citationSlamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.353 · Cited by 281
Self-citationIntegrating Old and New Paradigms of G1/S Control
Rubin, S. M., Sage, J., & Skotheim, J. M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.08.020 · Cited by 264
“Positive clinical trial results for pallbociclib (PALOMA 3), ribociclib (MONALEESA-7), and other inhibitors have validated Cdk4/6 as therapeutic targets in breast cancer (Im et al., 2019; Sledge et al., 2019; Spring et al., 2020; Turner et al., 2018), and it is likely that Cdk4/6 inhibitors will demonstrate efficacy i…”
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Self-citationAdjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02554 · Cited by 235
Self-citationJones, R. H., Casbard, A., Carucci, M., Cox, C., Butler, R., Alchami, F., Madden, T.-A., Bale, C., Bezecny, P., Joffe, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30817-4 · Cited by 229
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 224
“The SOLAR-1 clinical trial started to recruit the first patients during the second half of 2015, a few months after the FDA granted accelerated approval for the CDK4/6 inhibitor palbociclib in combination with endocrine treatment for postmenopausal HR+/HER2metastatic breast cancer [85,86].”
MethodBreast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 214
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Cyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Kalinsky, K., Accordino, M. K., Chiuzan, C., Mundi, P. S., Sakach, E., Sathe, C., Ahn, H., Trivedi, M. S., Novik, Y., Tiersten, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02392 · Cited by 210
“The following will be assessed when requests are received: (1) legitimacy and relevance, (2) whether the requests are within the scope of the participants’ informed consent, and (3) compliance with regulations with respect to the trial.”
Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics
Kar, R., Dhar, R., Mukherjee, S., Nag, S., Gorai, S., Mukerjee, N., Mukherjee, D., Vatsa, R., Chandrakanth Jadhav, M., Ghosh, A., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01329 · Cited by 210
Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., González Farré, B., Fernández, P. L., Galván, P., Chic, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30786-7 · Cited by 202
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Fusco, G., Martinelli, C., Nuzzo, F., Pensabene, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186479 · Cited by 200
Breast cancer treatment: A phased approach to implementation
Mutebi, M., Anderson, B. O., Duggan, C., Adebamowo, C., Agarwal, G., Ali, Z., Bird, P., Bourque, J., DeBoer, R., Gebrim, L. H., et al. (2020) · Cancer · doi:10.1002/cncr.32910 · Cited by 187
Bidard, F.-C., Jacot, W., Kiavue, N., Dureau, S., Kadi, A., Brain, E., Bachelot, T., Bourgeois, H., Gonçalves, A., Ladoire, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5660 · Cited by 181
Targeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 185
“, fulvestrant) or mutantselective agents (BRAF inhibitors) (Im et al., 2019; Long et al., 2015; Robert et al., 2019) the additive or synergistic activity is confined to the tumor, thus resulting in a better than expected TI for the combination.”
Markham, M. J., Wachter, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C. S. M., Rodriguez-Galindo, C., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 171
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Beavers, C. J., Rodgers, J. E., Bagnola, A. J., Beckie, T. M., Campia, U., Palo, K. E. D., Okwuosa, T. M., Przespolewski, E. R., & Sj, D. (2022) · Circulation · doi:10.1161/cir.0000000000001056 · Cited by 187
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
“The positive PFS and overall survival (OS) results further strengthen AI ’ s role as a partner in fi rst-line treatment of CDK4/6i [22, 23].”
BackgroundClinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
George, M. A., Qureshi, S., Omene, C. O., Toppmeyer, D., & Ganesan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693104 · Cited by 163
“In ER+ breast cancer, they work synergistically with anti-estrogen therapies such as aromatase inhibitors, Fulvestrant and tamoxifen (1, 2, 4, 7, 17, 18).”
BackgroundGyawali, B., Hey, S. P., & Kesselheim, A. S. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100332 · Cited by 162
“However, some drugs such as ribociclib (Kisqali) in first-line treatment of breast cancer approved on the basis of changes to a surrogate measure have demonstrated improved OS later [33].”
BackgroundTargeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Prat, A., Chaudhury, A., Solovieff, N., Paré, L., Martinez, D., Chic, N., Martínez‐Sáez, O., Brasó‐Maristany, F., Lteif, A., Taran, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02977 · Cited by 164
“Recently, the addition of cyclindependent kinase 4 and 6 (CDK4/6) inhibitors to ET has been considered the standard therapy for most patients with HR1 and HER22 ABC because of clinically meaningful increases in both progressionfree survival (PFS)(3-5) and overall survival (OS).(6,7) In this context, no prognostic and/…”
BackgroundSelf-citationO’Brien, N. A., McDermott, M. S. J., Conklin, D. F., Luo, T., Ayala, R., Salgar, S., Chau, K., DiTomaso, E., Babbar, N., Su, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01320-8 · Cited by 155
“crine therapies significantly improves progression-free survival (PFS) overall survival [1] in patients with advanced estrogen receptor-positive /HER2-negative (ER+/ HER2−) breast cancer [2–4] and is now the standard of”
BackgroundSelf-citationGrinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P. H., Dieras, V. C., Dalenc, F., Gonçalvès, A., Debled, M., Patsouris, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100114 · Cited by 154
“Beyond progression-free survival benefits, two of these CDK4/6 inhibitors have demonstrated improvements in OS.(10,13) Finally, eribulin allowed a 2-months OS improvement in HER2e MBC patients and was released in this indication in the early 2010s(14) (Supplementary Figure S1, available at https://doi.”
BackgroundInfluentialBaelen, K. V., Geukens, T., Maetens, M., Tjan‐Heijnen, V. C. G., Lord, C. J., Linn, S., Bidard, F., Richard, F., Yang, W. W., Steele, R. E., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.006 · Cited by 159
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Crozier, L., Foy, R., Mouery, B. L., Whitaker, R. H., Corno, A., Spanos, C., Ly, T., Cook, J. G., & Saurin, A. T. (2022) · The EMBO Journal · doi:10.15252/embj.2021108599 · Cited by 154
The History of Early Breast Cancer Treatment
Ben-Dror, J., Shalamov, M. M., & Sonnenblick, A. (2022) · Genes · doi:10.3390/genes13060960 · Cited by 167
“MONALEESA-7 examined ribociclib or placebo plus ET (AI or tamoxifen) in premenopausal and perimenopausal women and showed significantly longer PFS and overall survival in the ribociclib arm [45].”
MethodEndocrine-Resistant Breast Cancer: Mechanisms and Treatment
Hartkopf, A. D., Grischke, E., & Brucker, S. Y. (2020) · Breast Care · doi:10.1159/000508675 · Cited by 149
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 142
Park, Y. H., Kim, T., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., Lee, M. H., Kim, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30565-0 · Cited by 134
Self-citationMartín, M., Zielinski, C. C., Ruíz‐Borrego, M., Carrasco, E., Turner, N. C., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Anton, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.013 · Cited by 147
Oshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Nagahashi, M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cells · doi:10.3390/cells9071643 · Cited by 142
“The xCell algorithm provided tumoral compositional analysis for infiltrating immune cells based on tumoral genomic data [56].”
Hortobágyi, G. N., Łacko, A., Sohn, J., Cruz, F. M., Borrego, M. R., Manikhas, A., Park, Y. H., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.015 · Cited by 133
Self-citationBardia, A., Hurvitz, S. A., DeMichele, A. M., Clark, A. S., Zelnak, A. B., Yardley, D. A., Karuturi, M. S., Sanft, T. B., Blau, S. H., Hart, L. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2114 · Cited by 136
Self-citationDrugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 140
García‐Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B., Garrido-Castro, A. C., Pascual, T., de Cubas, A. A., Xia, Y., Felsheim, B., McClure, M. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00491-x · Cited by 193
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 123
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 128
Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 126
Targeting Autophagy in Breast Cancer
Cocco, S., Leone, A., Piezzo, M., Caputo, R., Lauro, V. D., Rella, F. D., Fusco, G., Capozzi, M., Gioia, G. D., Budillon, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217836 · Cited by 121
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 122
Ciruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 118
Onesti, C. E., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852934 · Cited by 127
Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 120
“Diarrhea 13 (65) 2 (10) 26 (59) 2 (5) 39 (61) 4 (6)”
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
McAndrew, N. P., & Finn, R. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00384 · Cited by 121
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Rella, F. D., Fusco, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176400 · Cited by 119
“5 mg/day in the MONALEESA-2 trial for AI-sensitive post-menopausal women [25,26,28,52–54], in combination with tamoxifene or NSAI (with goserelin to suppress ovarian function) in premenopausal AI-sensitive women in the MONALEESA-7 trial [28,55], and in combination with fulvestrant both for AI-sensitive and AI-resistan…”
BackgroundZhang, P., Zhang, Q., Tong, Z., Sun, T., Li, W., Ouyang, Q., Hu, X., Cheng, Y., Yan, M., Pan, Y., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00172-9 · Cited by 125
Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
Khatpe, A. S., Adebayo, A. K., Herodotou, C., Kumar, B., & Nakshatri, H. (2021) · Cancers · doi:10.3390/cancers13030369 · Cited by 115
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Slamon, D. J., Fasching, P. A., Hurvitz, S. A., Chia, S., Crown, J. P., Martín, M., Barrios, C. H., Bardia, A., Im, S., Yardley, D. A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231178125 · Cited by 119
“67 16–18 In the advanced setting, AEs associated with ribociclib are mostly asymptomatic, and patients reported improved or maintained QOL during treatment.”
BackgroundInfluentialSelf-citationCrozier, L., Foy, R., Adib, R., Kar, A., Holt, J. A., Pareri, A. U., Valverde, J. M., Diazgranados, R. R., Weston, W. A., Wilson, R., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.016 · Cited by 106
Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Mastro, L. D., Puglisi, F., Placido, S. D., Paris, I., Placido, P. D., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa071 · Cited by 111
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102
Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M. V., & Guarneri, V. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100409 · Cited by 109
Lindeman, G. J., Fernando, T. M., Bowen, R. L., Jerzak, K. J., Song, X., Decker, T. W., Boyle, F. M., McCune, S., Armstrong, A. C., Shannon, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3811 · Cited by 103
Self-citationPooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
André, F., Su, F., Solovieff, N., Hortobágyi, G. N., Chia, S., Neven, P., Bardia, A., Tripathy, D., Lu, Y.-S., Lteif, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.011 · Cited by 121
Self-citationBurris, H. A., Chan, A., Bardia, A., Beck, J. T., Sohn, J., Neven, P., Tripathy, D., Im, S., Chia, S., Esteva, F. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01415-9 · Cited by 105
Self-citationLu, Y., Mahidin, E. I. B. M., Azim, H. A., Eralp, Y., Yap, Y. S., Im, S., Rihani, J., Gökmen, E., Bastawisy, A. E., Karadurmuş, N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00144 · Cited by 111
“18,20,21 15-19, 22”
Self-citationDe Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Lloyd, M. R., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2947 · Cited by 101
Self-citationFassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 102
Yuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Padam, S., Tang, A., Martínez, N., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.035 · Cited by 97
Konstantinopoulos, P. A., Lee, E. K., Xiong, N., Krasner, C. N., Campos, S. M., Kolin, D. L., Liu, J. F., Horowitz, N. S., Wright, A. A., Bouberhan, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00628 · Cited by 99
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
“GnRH agonists are often administered in combination with cyclofosfamide [108], tamoxifen [109], or cyclin-dependent kinase 4/6 inhibitor [110,111] in the adjuvant or metastatic settings in patients with premenopausal or perimenopause endocrine positive BC.”
Alves, C. L., Ehmsen, S., Terp, M. G., Portman, N., Tuttolomondo, M., Gammelgaard, O. L., Hundebøl, M. F., Kaminska, K. K., Johansen, L. E., Bak, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25422-9 · Cited by 97
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
Hao, C., Wei, Y., Meng, W., Zhang, J., & Yang, X. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102861 · Cited by 99
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01701-9 · Cited by 83
“…+ NSAI versus NSAI alone (mOS, not reached [NR] vs. 40.7 months [HR 0.70; 95% CI 0.50–0.98]) in pre/perimenopausal women; in addition, an exploratory analysis with extended follow-up reported an mOS of 58.7 versus 47.7 for ribociclib + NSAI versus NSAI alone (HR 0.798; 95% CI 0.62–1.04) [15, 16].”
InfluentialSelf-citationRoncato, R., Angelini, J., Pani, A., Cecchin, E., Bianchi, A. S., Siena, S., Mattia, E. D., Scaglione, F., & Toffoli, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176350 · Cited by 85
“In the MONALEESA-7 trial ribociclib showed similar efficacy in combination with ovarian suppressor and tamoxifen or aromatase inhibitor at the same setting in premenopausal women [9].”
The immunomodulatory effects of endocrine therapy in breast cancer
Huang, H., Zhou, J., Chen, H., Li, J., Zhang, C., Jiang, X., & Ni, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01788-4 · Cited by 95
“Moreover, regimens targeting the cell cycle regulatory protein CDK4/6 in combination with anti-estrogen regimens (SERDs/AIs) have also been demonstrated to greatly improve the prognosis of ERα + BC [8, 9].”
BackgroundDesnoyers, A., Nadler, M. B., Kumar, V., Saleh, R., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102086 · Cited by 88
Li, J., Huo, X., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20312 · Cited by 95
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.